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Abstract
Background On 30 January 2012, the US FDA approved
vismodegib (Erivedge, Genentech, CA, USA) for the
management of both metastatic and locally advanced basal
cell carcinoma.
Objective Our objective was to identify evidence of hep-
atotoxicity with vismodegib in the FDA Adverse Event
Reporting System (FAERS) in treated patients in two
National Cancer Institute Comprehensive Cancer Centers.
Methods FAERS was searched for reports dated 1 January
2009 through 31 December 2015 using terms including
hedgehog pathway and vismodegib and hepatic-related
terms such as liver, jaundice, and hepatitis, among others.
Disproportionality analyses with estimates of proportional
reporting ratio and empirical Bayesian geometric mean
were conducted. A comprehensive literature review was
conducted, and the clinical databases at the University of
Texas MD Anderson Cancer Center and Robert H. Lurie
Comprehensive Cancer Center of Northwestern University
were searched.
Results Two cases of severe liver dysfunction were pub-
lished (Common Terminology Criteria for Adverse Events
[CTCAE] class III), and 94 reports of adverse events (AEs)
were detected in FAERS, 35 of which were serious AEs.
Safety notifications related to hepatotoxicity have not been
issued by the manufacturer or the FDA, although vismod-
egib is listed in LiverTox and the European Medicines
Agency website.
Conclusion We identified a detectable safety signal for
hepatotoxicity for vismodegib within 4 years of FDA
approval. Vismodegib should be used in patients with
severe liver disease only after careful consideration, and
concomitant hepatotoxic medications should be avoided.
Rapid dissemination of such safety concerns is expected to
result in fewer serious hepatotoxic AEs and more optimal
outcomes for patients with cancer receiving vismodegib.
Electronic supplementary material The online version of this
article (doi:10.1007/s40268-016-0168-2) contains supplementary
material, which is available to authorized users.
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Key Points
Hepatotoxicity has been reported as an aderse event
with Vismodegib.
Vismodegib is listed as a hepatotoxic medication in
the LiverTox site. The European Medicine Agency
reports the elevation of liver enzymes, and the
Australian Therapeutic Goods Administration
reported 3 cases of hepatotoxicty resulting in
hospitalizatons with vismodegib.
The assessmen of liver profile prior to vismodegib
use, and its avoidance in patients with moderate to
severe liver disease is recommended. Consider
avoidance of concomitant medications with hepatic
metabolism. Recommend that safety
recommendations be incorporated into the FDA
website, and product package insert.
1 Introduction
About eight in ten skin cancers are basal cell carcinomas
(BCCs) [1], making it the most common type of skin
cancer, arising from the lower layer of the skin. In 2014,
more than 2 million estimated new cases and 1000 deaths
occurred in the USA [2]. Surgery followed by radiation
offers the most effective and efficient means for cure.
Therapies such as 5-flurouracil, imiquimod, photodynamic
therapy, or vigorous cryotherapy can be considered as
alternative treatments for individuals with low-risk super-
ficial BCC [3].
On 30 January 2012, the US FDA approved vismodegib
for the treatment of recurrent, locally advanced, or meta-
static BCC, based primarily on the results observed in a
single-arm parallel-cohort international trial [4]. An overall
response rate of 43 and 30% was seen in patients with
localized and metastatic BCC [5].
The most common adverse events (AEs) associated with
vismodegib reported in randomized controlled trials
(RCTs) were muscle spasms, alopecia, dysgeusia, weight
loss, fatigue, loss of appetite, and upper respiratory tract
infections [4, 6]. One case of severe hepatotoxicity with
vismodegib was reported in an 83-year-old female subject
[7]. This individual’s medical history included hyperten-
sion, atrial fibrillation, and chronic obstructive pulmonary
disease but no evidence of prior liver abnormalities. After
1 week of treatment, she developed nausea and emesis and
was hospitalized. Liver function tests revealed a cholestatic
pattern of hepatotoxicity, and liver biopsy exhibited non-
specific cholestasis with portal fibrosis. Other RCTs in
advanced BCC [8] and ovarian cancer [9] have listed, less
commonly, elevation of hepatic enzymes and abdominal
pain.
The FDA Adverse Event Reporting System (FAERS) is
a self-reported and voluntary database of AEs and medi-
cation errors reported to the FDA. It is designed to support
the FDA’s post-marketing safety surveillance program for
drugs and therapeutic biological products. FAERS data can
be used to identify post-marketing safety signals. A safety
signal is defined by the Working Group VIII of the Council
for International Organizations of Medical Sciences
(CIOMS VIII) as ‘‘Information that arises from one or
multiple sources (including observations and experiments),
which suggests a new potentially causal association, or a
new aspect of a known association, between an interven-
tion and an event or set of related events, that is judged to
be of sufficient likelihood to justify further verification’’
[10]. Limitations include no proven causal relationship
between events and a certain product and potential
reporting bias [11].
The Research on Adverse Drug events And Reports
(RADAR) project has received National Cancer Institute
(NCI) and National Science Foundation (NSF) funding for
pharmacovigilance activities. Based at Northwestern
University, RADAR was first initiated in 1998 by a mul-
tidisciplinary investigator team that systematically inves-
tigated and disseminated information describing serious
and previously unrecognized adverse drug and device
reactions (ADRs) [12]. The purpose of this study was to
determine whether a safety signal for vismodegib-related
hepatotoxic AEs is detectable in FAERS and to search the
clinical databases of two NCI-designated Comprehensive
Cancer Centers in two large urban settings (Houston and
Chicago, USA), The University of Texas MD Anderson
Cancer Center and R.H. Lurie Comprehensive Cancer
Center (RHLCCC) of Northwestern University,
respectively.
2 Methods
This retrospective study was approved by the Institutional
Review Boards of MD Anderson Cancer Center and
Northwestern University. RADAR methodology has been
previously described in detail [12]. We searched FAERS
for vismodegib and adverse liver event as combined terms
from 1 January 2009 through 31 December 2015. All
hepatic cases were identified through a search including
ascites, hepatobiliary disease, liver toxicity, hepatitis, and
cholestasis, among others. Complete search terms are listed
in Appendix I in the Electronic Supplementary Material.
Within FAERS, we calculated disproportionate report-
ing of hepatic dysfunction using proportional reporting
212 B. J. Edwards et al.
ratios (PRRs) with 95% confidence intervals (CIs). PRRs
determined whether the proportion of FAERS cases with
hepatic dysfunction was higher in patients receiving vis-
modegib than in those receiving other drugs. The PRR is a
statistical aid that generates signals based on a propor-
tionate approach, which also acknowledges the stability of
a large database. PRRs involve calculation of the propor-
tions of specified reactions for drugs of interest, with the
comparator being the proportions of the specified reactions
reported among all other drugs in the database. Judgment
about the existence of a signal and its strength is made
based on three pieces of information: the PRR, the chi-
squared value of the data, and the number of cases. A
signal is defined as a PRR of C2, a chi-squared value C4,
and three or more cases reported to FAERS [12, 13].
The clinical databases at MD Anderson Cancer Center
and RHLCCC were queried to detect individuals exposed
to vismodegib. Medical records of these cases were
reviewed, and data on demographics (age, sex, race/eth-
nicity, type of cancer) and liver function tests were col-
lected. In addition, three major electronic databases were
searched (MEDLINE, PubMed, and Embase) for peer-re-
viewed articles published between 1970 and 31 March
2014 using terms such as vismodegib, GDC-0449, sonic
hedgehog, neoplasm, and clinical trials. The literature
review obtained information on the results of clinical trials
of vismodegib reporting on efficacy and adverse effects.
We also searched websites and safety databases maintained
by the FDA and other major international regulatory
agencies.
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 was used as toxicity grading criteria
for AE reporting. A grading (severity) scale is provided for
each AE term (grade 1: mild AE; grade 2: moderate AE;
grade 3: severe AE; grade 4: life-threatening or disabling
AE; grade 5: death related to AE) [14]. For hepatotoxicity
cases detected within FAERS, concomitant drugs were
reviewed; those with significant hepatic metabolism were
identified based on information contained within multiple
databases [15].
3 Results
3.1 FDA Adverse Event Reporting System (FAERS)
Results
In total, 94 FAERS cases were reported as having at least
one AE of liver dysfunction, with 35 reports including
terms demonstrating severe hepatotoxicity (Table 1), all of
which were reported to FAERS by the sponsor. Of 35
reports, 20 were serious AEs (SAEs) resulting in hospi-
talization or death. Other AEs with these cases included
dysphagia, abdominal discomfort, and cognitive disorders.
The mean age of all 35 individuals was 60 years (range
0–98); 16 were female and 16 were male (of the 32 FAERS
cases in which sex was reported). Comorbidities were
infrequently reported and included hypertension (3/35),
diabetes mellitus (2/35), hypothyroidism (1/35), and acute
respiratory distress syndrome (1/35). Signal-detection
analyses resulted in PRRs of 2.71 (95% CI 2.3–3.2) among
all hepatic dysfunction cases and 2.24 (95% CI 1.7–2.9)
among serious hepatotoxicity cases, and reflect a signifi-
cant safety signal.
3.2 University of Texas MD Anderson Cancer
Center and Robert H. Lurie Cancer Center
Results
In total, 15 patients received vismodegib in two cancer
centers: for BCC (n = 13) and for medulloblastoma
(n = 2). Two cases experienced elevated alkaline phos-
phatase (twofold elevation).
4 Discussion
We ascertained that hepatic events associated with vis-
modegib in FAERS produced a safety signal. This associ-
ation was previously described in the study by Ventarola
and Silverstein [16]. We identified an increasing incidence
over the extended study period. The first case was reported
prior to FDA approval in 2011, and there has been an
upward trend in cases reported to FAERs over the last
4 years (Fig. 1). It has been reported that a median of
7 years post-marketing elapses before newly detected
SAEs are announced by pharmaceutical suppliers and/or
the FDA [17], but this report of vismodegib-associated
hepatotoxicity is being disseminated within 4 years of
approval. The importance of systematic interrogation and
analyses with large databases such as FAERS is made
evident in that, in two NCI-designated comprehensive
cancer centers, initial interrogation showed no
detectable reports of hepatotoxicity. Such a finding is not
unexpected, given the small number of treated patients
(n = 15) in two of the NCI-designated 41 comprehensive
cancer centers. Since hepatotoxicity may progress to be
severe and/or life threatening, further exploration of this
important association is essential. According to the NCI,
only about 15% of US cancer patients are diagnosed and
treated at the nation’s major academic-based cancer cen-
ters, and the large remainder may not be easily tracked for
outcomes [18]. Moreover, since FAERS case reports are
de-identified, it is not practical to ascertain, and/or contact
the initial reporter for, further clinical information and
outcomes. Moreover, FAERS reports of vismodegib-
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associated hepatotoxicity typically do not provide detail on
related comorbidities such as prior liver abnormalities or
alcohol abuse.
Some possible mechanisms of drug-related hepatotoxi-
city include disruption of the cell membrane and drug
binding to cell protein, leading to cell death; cell apoptosis;
inhibition of cell mitochondria function; cellular pathway
inhibition; and abnormal bile flow leading to cholestasis
and jaundice. Moreover, obesity and malnutrition, preg-
nancy, history of drug reactions, and pre-existing liver
disease are factors that lead to susceptibility to hepato-
toxicity [19]. Liver abnormalities may also include etio-
logical factors such as nonalcoholic steatohepatitis
(NASH), medication use, alcohol use, and chronic liver
disease, among others [20].
In published RCTs, vismodegib resulted in elevated ala-
nine aminotransferase levels compared with the placebo arm
[21]. SAEs (CTCAE grade 3–4) were seen in two partici-
pants in an ovarian cancer RCT [9]. Hedgehog signaling has
generally been considered inactive in healthy adult hepato-
cytes. Paracrine connections with hepatic epithelial cells are
important for embryonic development, cell proliferation, and
recovery from chronic liver damage [22–24]. Vismodegib
functions as a small-molecule inhibitor of the hedgehog
pathway by binding to smoothened (SMO) receptors in cells.
Therefore, it may be reasonable to hypothesize that the
damage caused by NASH creates an idiosyncratic trait
within patients, placing them at a higher risk for experi-
encing a liver-based AE if they are treated with vismodegib
as the drug attempts to regulate a highly damaged system.
Concomitant medication use, summarized in FAERS for
14 of the serious cases, may prove to be quite important, as
four of the reports in FAERS indicated concomitant use of
acetaminophen, a common over-the-counter medication
(Table 1). Acetaminophen may lead to acute hepatotoxicity
or necrosis, especially with overdose; acetaminophen poi-
soning accounts for nearly 50% of all cases of acute liver
failure in the USA [25]. Ash and Jolly [26] reported a case
of acute liver injury related to a possible drug–drug
interaction between vismodegib, aspirin, and naproxen.
Thus, concomitant drug use with vismodegib may con-
tribute to drug–drug interactions that may play a major role
in the development of liver toxicity.
The press announcement at the time of the original FDA
approval on 30 January 2012 and the DailyMed website, on
which full prescribing information documents are posted
by the US National Library of Medicine, both specified that
safety and effectiveness were not established for patients
with hepatic impairment who receive vismodegib [27–29].
LiverTox currently lists vismodegib as a potentially hepa-
totoxic medication [30]. Health Canada has a statement
similar to that of the FDA in relation to liver impairment
but with an arrangement whereby the sponsor agrees to
submit additional safety studies, specifically to include
results from a renal/hepatic impairment study by March
2015 [31]. The European Medicines Agency (EMA)
reported that data on moderate and severe liver impairment
were too limited to enable conclusions about liver
impairment, but nevertheless posted a table including
abnormal liver enzymes as a common side effect in 1–10%
of patients [32]. The Australian Government’s Therapeutic
Goods Administration released a statement citing study
SHH4489g, which attributed three cases of hepatotoxicity
to vismodegib, cases resulted in hospitalizations, but no
deaths were reported [33]. The agency recommended vis-
modegib be avoided in patients with severe hepatic
impairment [33]. As such, although the FDA labeling (full
prescribing information) mentions that medications that are
liver metabolized should be avoided, it provides no infor-
mation on drug interaction risks for vismodegib [27, 28].
Especially in light of healthcare system reform, busy health
practitioners must access and utilize ever-increasing
amounts of information in the prescribing of medications
and patient management, with a continuous need for new
and updated post-marketing risk information and newly
identified clinically significant drug interactions [34].
In contrast with other drug regulatory agencies, the FDA
has not yet advanced newly evolving risk information
regarding vismodegib and hepatotoxicity, although it has
issued recommendations for studies of vismodegib use in
individuals with renal and liver dysfunction [29]. Patients
with mild liver impairment should be carefully monitored if
vismodegib is considered for therapy. We also recommend
that potentially hepatotoxic agents such as acetaminophen
and alcohol be avoided during vismodegib therapy.
Limits of this study may include under-reporting and
potential reporting bias because of the voluntary nature of
the FAERS database and the impracticability of contacting
AE reporters. As such, the ability to establish causality of
hepatotoxicity associated with vismodegib based on
FAERS data is limited, albeit significant signal detection
values were found.
Fig. 1 Severe cases reported in the US FDA Adverse Event
Reporting System by year
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5 Conclusion
Given a detectable safety signal for hepatotoxicity within
FAERS for vismodegib, its use in patients with severe liver
disease should include careful consideration of risk versus
benefit. We recommend close monitoring of liver function
and cautious use with concomitant hepatotoxic medica-
tions. As such, the FDA decision to waive Risk Evaluation
and Mitigation Strategies (REMS) as part of its vismodegib
labeling may require re-evaluation and carefully conducted
prospective pharmacovigilance studies to achieve safe use.
Rapid dissemination of such safety concerns is expected to
result in fewer serious hepatotoxic adverse events and more
optimal outcomes for patients with cancer receiving
vismodegib.
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